Summary
Thirty-three patients with relapsing or refractory multiple myeloma were treated with 6-Thioguanine (6TG) at a dose of lg/M2, with therapy given over four hours every three weeks. The major toxicity seen was myelotoxicity; thrombocytopenia was more commonly noted than neutropenia. One patient achieved a PR, two were clinically improved. 6TG in this short infusion schedule proved to be myelotoxic, but demonstrated little activity in previously treated myeloma patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG: Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a southwest oncololy group study. J Clin Oncol 1: 453–461, 1983
Harley JB, Pajak TF, McIntyre OR, Kochwa S, Cooper MR, Coleman M, Cuttner J: Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: a study of the CALGB. Blood 54: 13–22, 1979
Durie BGM, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi J: Improved survival duration with combination chemotherapy induction for multiple myeloma. J Clin Oncol 1227-1237, 1986
Chabner BA, Myers CE: Clinical pharmacology of cancer chemotherapy in principles and practice of oncology, JB Lippincott Co. Devita, Hellman Rosenberg (eds) Philadelphia 1982, pp 156–172
Carbone PP, Frei E, Owens AH, Olson KB, Miller SP: 6-Thioguanine NSC-752 therapy in patients with multiple myeloma. Cancer Chemo Rep 6: 59–62, 1964
Presant CA, Denes AE, Liu C, Bartolucci AA: Prospective randomized reappraisal of 5-Fluorouracil in metastatic colorectal carcinoma. tA comparative trial with 6-Thiogua-nine. Cancer 53: 2610–2614, 1984
Minutes of the New Drug Liason Meeting, October 1, 1980
Valeriote F, Grates H: MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma. J Nat'l Cancer Inst 76: 61–65, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Edelstein, M.B., Crowley, J.J., Valeriote, F.A. et al. A phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. Invest New Drugs 8 (Suppl 1), S83–S86 (1990). https://doi.org/10.1007/BF00171990
Issue Date:
DOI: https://doi.org/10.1007/BF00171990